Natera Inc
F:45E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Natera Inc
F:45E
|
US |
|
A
|
Advantest Corp
F:VAN
|
JP |
|
A
|
Advantest Corp
XMUN:VAN
|
JP |
Intrinsic Value
The intrinsic value of 
Natera Inc (45E) under the Base Case is 49.45 EUR per share.
Compared with the current market price of 86 EUR, the stock appears
Overvalued by 42% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Natera Does
Natera is a genetic testing company that analyzes DNA from blood, saliva, or tissue samples to help doctors make medical decisions. Its main products are tests for prenatal screening, hereditary cancer risk, and transplant monitoring, along with tests that help guide care for people with certain cancers. The company sells these tests to hospitals, doctors, cancer centers, and specialty clinics, and it makes money when those tests are ordered and processed.
- Headquarters
- United States of America US
- Employees
- 6 135
- IPO date
- Jul 2, 2015
Natera has a narrow economic moat
Patents protect parts of Natera’s genetic testing methods, while approval to guide a specific bladder cancer treatment gives Signatera a role that rivals cannot simply copy. Its patient-specific test setup also gives doctors a practical reason to keep ongoing monitoring with Natera. These protections apply most clearly to cancer testing rather than equally across all its markets.
Read the full moat analysis
Revenue & Expenses Breakdown
Natera Inc
Earnings Waterfall
Natera Inc
The intrinsic value for Natera Inc (45E) under the Base Case is 49.45 EUR.
Compared with the current market price of 86 EUR, the stock appears Overvalued by 42% .